According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX).
The deal would potentially bolster Sanofi’s drug pipeline, helping the company to reduce its reliance on the blockbuster asthma medicine Dupixent.
Sanofi’s backing would also help Mirati commercialize Krazati and fund treatment and further studies, Bloomberg noted.
In December, Mirati received FDA accelerated approval for Krazati, a second-line treatment for lung cancer with mutated KRAS genes, though European regulators issued a negative opinion on the conditional approval for the medicine.
Thursday, FDA advisers concluded that the data from a late-stage trial lacked the requisite …
